Three COVID-19 Drug Trials Stopped After Participants Become Ill, an Industrial Info Market Brief

With the hyper-accelerated pace underway to develop a viable COVID-19 vaccine and treatments in a fraction of the time normally required, it is inevitable that problems would crop up. This is all part of the drug development process. The risk factor rises with the number of people participating in the trials.